Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2015-04-17 | Dr. Chaplin served as a non-employee director in fiscal year 2014 until his appointment as our President and CEO in May 2014. The compensation set forth opposite Dr. Chaplin's name in this table reflects his compensation as a non-employee director only in fiscal year 2014. The following table shows the total compensation paid or accrued during the fiscal year ended December 31, 2014 to each of our non-employee directors. Directors who are employed by us are not compensated for their service on our Board of Directors. David J. Chaplin: Fees Earned or Paid in Cash ($): 30,000; Stock Awards($): 0; Option Awards($): 0; All Other Compensation ($): 10,000; Total: 40,000. Dr. Chaplin provides consulting services to us. The compensation reported in this column reflects payments for such consulting services rendered during fiscal year 2014 prior to his appointment as our President and CEO in May 2014. We paid Dr. Chaplin approximately $53,625 as compensation for services performed under this consultancy agreement during our 2014 fiscal year through May 15, 2014. |
| 2016-04-25 | Since May 2015, Dr. Chaplin has served as OXiGENE's Chief Scientific Officer. Dr. Chaplin also provides consulting services to OXiGENE through Aston Biopharma Ltd., a UK-based entity which is controlled by Dr. Chaplin. The compensation Dr. Chaplin received from the Company as further described under Executive Compensation includes compensation received under our consultancy agreement with Aston Biopharma LTD. |
| 2017-04-26 | Dr. Chaplin has served as Mateon’s Chief Scientific Officer since May 2015 and is a director since 2013. He was President and CEO from May 2014 to May 2015. |
| 2018-05-07 | The following table sets forth certain information about each nominee. The ages of the nominees are as of March 30, 2018. David J. Chaplin, Ph.D. Director |
Data sourced from SEC filings. Last updated: 2026-02-03